Medicine Description faglozino 25mg
faglozino 25mg tablets is a medication that contains empagliflozin, which functions as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. By inhibiting the SGLT2 protein located in the proximal tubules of the kidneys, empagliflozin reduces the reabsorption of glucose and sodium back into the bloodstream. This mechanism increases urinary glucose excretion, thereby lowering blood glucose levels. Additionally, the reduction in sodium reabsorption leads to osmotic diuresis, which can decrease blood pressure and improve cardiovascular outcomes. This dual action not only helps in managing hyperglycemia in type II diabetes but also offers protective cardiovascular benefits, particularly in patients with pre-existing cardiovascular conditions.
Indications and Uses of faglozino 25mg tablets
- Management of type II diabetes mellitus as an adjunct to diet and exercise.
- Reduction in the risk of cardiovascular events in patients with type II diabetes and established atherosclerotic cardiovascular disease.
Side Effects of faglozino 25mg tablets
- Dehydration due to increased urination.
- Urinary tract infections.
- Genital mycotic infections.
- Hypotension, particularly in patients experiencing volume depletion.
- Elevated serum creatinine levels.
Storage and Handling
Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
Patient Advice and Precautions
Patients should be advised to maintain adequate hydration and monitor for signs of urinary tract infections or dehydration. It is important to inform healthcare providers about any other medications being taken to avoid potential interactions. Regular blood glucose monitoring is recommended to assess the effectiveness of therapy.